Heat Biologics (HTBX) Stock Price Down 9.3%

Heat Biologics, Inc. (NASDAQ:HTBX)’s share price traded down 9.3% during mid-day trading on Thursday . The stock traded as low as $0.38 and last traded at $0.39. 579,900 shares changed hands during trading, a decline of 4% from the average session volume of 603,963 shares. The stock had previously closed at $0.43.

Separately, Griffin Securities started coverage on Heat Biologics in a research report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $2.13.

Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. The firm had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.50 million. equities research analysts anticipate that Heat Biologics, Inc. will post -0.38 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. boosted its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the period. Vanguard Group Inc. owned 1.86% of Heat Biologics worth $403,000 as of its most recent SEC filing. 8.37% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Heat Biologics (HTBX) Stock Price Down 9.3%” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3080454/heat-biologics-htbx-stock-price-down-9-3.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.